
|Articles|July 7, 2006
ISTA gains licenses to two investigational treatments for glaucoma
ISTA Pharmaceuticals gained exclusive North American rights to Senju Pharmaceuticals' iganidipine, a calcium-channel blocker, and a new formulation of latanoprost, a prostaglandin analogue.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement